NGS Panels – From Patient Selection to CDx
NGS panels are a powerful tool for parallel assessment of genomic integrity and expression across multiple targets. This facilitates biomarker discovery in early phase clinical trials and also subsequent development of CDx assays with potential utility across multiple drug targets.
In this webinar, Dr Cheryl McFarlane, Operations Manager at Almac Diagnostic Services will summarise the main considerations of development and analytical validation of such panels and describe our experience identifying important technical and regulatory challenges.
Topics covered include:
- Use of NGS panels for patient selection
- Biomarker Discovery pathway in early phase trials
- A customised CDx Development approach
- Regulatory challenges and solutions
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.